The goal of this clinical research study is to find the highest tolerable dose of the
combination of dasatinib and crizotinib that can be given to patients with advanced cancer.
The safety of this drug combination will also be studied.
Dasatinib is designed to block certain proteins from causing cancer cells to grow out of
control. This may cause the cancer cells to die.
Crizotinib is designed to block certain abnormal genes found in cancer cells. This may cause
the cancer cells to die.
This is an investigational study. Dasatinib is FDA approved and commercially available for
the treatment of leukemia. Crizotinib is FDA approved and commercially available for the
treatment of lung cancer. The combination of dasatinib and crizotinib is currently being used
for research purposes only.
Up to 176 participants will take part in this study. All will be enrolled at MD Anderson